Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Bravida Norway acquires Plato AS and strengthens its position in HVAC in Sunnmøre

Bravida acquires 100% of the shares in the HVAC company Plato AS in Sykkylven, which will be integrated in Bravida Norge AS. Plato AS has a turnover of approximately NOK 35 million and around 21 employees.Plato AS was founded in 1987 and is a HVAC contractor based in Sykkylven. The company’s main area of activity is installation and service work relating to HVAC systems, including heat pumps and plumbing. Its customers are mainly private companies, but also include consumers and public companies.  “We are very pleased to complete this acquisition. It will help us at Bravida to grow and

Wulff Group Plc’s Interim Report for January 1 – September 30, 2021

INTERIM REPORT OCTOBER 25, 2021 AT 9.30 A.M. This is a summary of Wulff Group Plc’s interim report for January-September 2021. Wulff Group’s interim report as a whole is attached as a PDF file to this stock exchange release and it is also available on the company’s website www.wulff.fi. The acquisition boosted growth and the positive earnings trend continued July 1–September 30, 2021 IN BRIEF · Net sales totalled EUR 24.2 million (12.4), increased by 95.1% · EBITDA and comparable EBITDA were EUR 1.7 million (1.3) · Operating profit (EBIT) and comparable operating profit (

Medivir Appoints Jens Lindberg as Chief Executive Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors  has appointed Jens Lindberg as CEO of the company. Jens Lindberg has extensive experience from the pharmaceutical industry and the field of Oncology. He joins from Sedana Medical where he has been VP Commercial and acting CEO.   Jens Lindberg started his career in the pharmaceutical industry in 1995 as a sales representative for Astra, later AstraZeneca. During a 25-year span at AstraZeneca, Jens held numerous roles in Commercial & Investor Relations, spanning local & global

Wicket Gaming signs letter of intent to acquire Wegesrand with a turnover of EUR 2.5 million

25[th] October 2021 kl. 08:30 CEST Wicket Gaming AB ("Wicket Gaming" or the "Company") has signed a letter of intent with the German group Wegesrand Verwaltungsgesellschaft mbH ("Wegesrand") to acquire all shares in Wegesrand with subsidiaries for a total purchase price of approximately EUR 4 million. Most of the purchase price will be paid with newly issued shares in Wicket Gaming which will be subject to a lock-up commitment. The letter of intent gives Wicket Gaming an exclusive right to conduct due diligence with the aim of signing a final purchase agreement around the end of 2021/2022.

Volvo Cars sets fixed listing price at SEK 53 per share and amends offering size

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Press release 25 October 2021Volvo Cars today announces the decision to amend the terms of its planned IPO on Nasdaq Stockholm. The update below follows the publication of Volvo Cars’ prospectus on 18 October 2021 and the announcement of Geely Sweden’s share conversion request on 22 October 2021. · The Board of Directors of Volvo Cars has today resolved to

BioStock: Sprint Bioscience receives research grant

Sprint Bioscience is constantly looking for highly interesting starting points for preclinical drug development projects, primarily in the field of cancer. Through a collaboration with Dr Julian Walfridsson at Karolinska Institutet, the company will identify new target proteins suitable for the treatment of blood cancer. The project has now been rewarded with a 2.5 MSEK research grant from the Swedish Foundation for Strategic Research.Read the full article at biostock.se:https://www.biostock.se/en/2021/10/sprint-bioscience-gets-research-grant/This is a press release from BioStock -

Gedea Biotech granted European Patent for its treatment pHyph for women with vaginal fungal infections

Patent now valid in two of the world’s largest markets, Europe and USA until 2037 Lund, Sweden, October 25, 2021. Swedish women’s health company Gedea Biotech today announced that the company has been granted a patent from the European Patent Office, covering the treatment of fungal infections with compound glucono-δ-lactone (GDL). The patent numbered EP 3 439 633 is valid in 36 European countries and can be kept in force until the 6th of April 2037. This follows previously announced patent rights valid in United States. Gedea Biotech has previously announced that the corresponding patent

2020 Bulkers Ltd. (2020) – Invitation to webcast and conference call Q3 2021 results

2020 Bulkers Ltd. will release its financial results for the third quarter of 2021 on Wednesday, October 27, 2021. A conference call and webcast will be held at 3:00 PM CET. The earnings report and presentation will be available from the Investor Relations section on www.2020bulkers.com on the same day. In order to listen to the presentation, you may do one of the following: Listen-only webcast (including the slide presentation): https://edge.media-server.com/mmc/p/6gzqv847 or you can click the “Webcast” link on www.2020bulkers.com/investor-relations/ Telephone conference Dial

Imfinzi improved survival in biliary tract cancer

25 October 2021 7:00 BST Imfinzi plus chemotherapy significantly improved overall survival in 1st-line advanced biliary tract cancer in TOPAZ-1 Phase III trial at interim analysis First immunotherapy combination to demonstrate superior clinical outcomesover standard of care in a global, randomised trial in this setting Positive high-level results from the TOPAZ-1 Phase III trial showed Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone

Metso Outotec expands Lokotrack mobile series for aggregates

Metso Outotec Corporation’s press release on October 25, 2021, at 09:00 a.m. EESTMetso Outotec is launching two new models to the Lokotrack® mobile crushing and screening series. The new Lokotrack LT200HPX and Lokotrack LT220GP mobile cone crushers are compact but efficient units ideal for aggregate contractor customers, bringing up to 30% more capacity and added flexibility compared to earlier models. The new models will be premiered during Metso Outotec’s virtual studio events on 27[th] October, and in the new Lokotrack Liveroom 360 online experience together with services and parts

Indutrade acquires Italian company specialised in critical fluids handling

Indutrade has on 22 October 2021 signed an agreement to acquire all of the shares in the Italian company Italprotec Industries S.r.l., italprotec.com , with annual sales of approximately EUR 10 million (SEK 100 million). The agreement was signed after the market closed.Italprotec is a manufacturer and technical trader of engineered industrial products for handling of critical fluids. The offering includes hoses, connectors, single-use assemblies, valves, fittings, and heat exchangers. The products ensure purity, corrosion resistance, and protection in sterile

Herantis Pharma Announces Members of Scientific Advisory Board

Herantis Pharma Plc, Press Release, 25 October 2021 at 9:00 EEST Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases, today announced the formation of a Scientific Advisory Board (SAB) comprised of industry leaders in CNS and neurodegenerative diseases, chaired by Dr. Anders Gersel Pedersen (as announcment September 14, 2021). The SAB will work cohesively with management to advance the company’s clinical development plan of rhCDNF (recombinant human CDNF) and HER-096 (xCDNF). “The prestigious group of scientific thought

Kindred’s revenue from harmful gambling 3.3 per cent in the third quarter

Kindred is determined to contribute to a more sustainable gambling industry across all markets through an open and fact-based dialogue. In the third quarter of 2021, Kindred’s share of revenue from harmful gambling decreased to 3.3 per cent.Kindred Group plc (Kindred) is committed to transform gambling by being a trusted source of entertainment that contributes positively to society. Therefore, Kindred has set an ambition to reach zero per cent of revenue from harmful gambling by the end of 2023 and to report this on a quarterly basis. The purpose is to be transparent, contribute to a fact-

Nitro Games Oyj: Interim Report January – September 2021

Reporting period January – September 2021 · Revenues (Jan - Sep): 1 404,6 KEUR (1 085,5 KEUR). · EBITDA: -2 059,9 KEUR (-1 449,4 KEUR). · EBIT: -2 474,5 KEUR (-1 791,9 KEUR). · Net result: -2 490,5 KEUR (-1 806,8 KEUR). · Earnings per share (EPS) -0,2 (-0,2). · Cash and cash equivalents: 3 666,6 KEUR (30 September 2021). (Numbers in brackets refer to the corresponding year-on-year period) July – September 2021 · Revenues (Jul - Sep): 969,1 KEUR (100,8 KEUR). · EBITDA: -512,1 KEUR (-819,5 KEUR). · EBIT: -626,1 KEUR (-933,7 KEUR). · Net result: -633,7

Invitation to presentation of Bactiguard’s interim report on October 28, 2021

Bactiguard Holding AB (publ) publishes the interim report for the third quarter on Thursday October 28, 2021 at 8:00 CET.In connection with this, an audiocast for investors, analysts and media will be held at 10:00 CET on October 28. CEO Anders Göransson and CFO Gabriella Björknert Caracciolo will present the interim report and answer questions. The report and a presentation for the audiocast will be available at Bactiguard’s website https://www.bactiguard.com. To participate in the audiocast, please use this link: https://tv.streamfabriken.com/bactiguard-q3-2021 To participate only

Josefin Lindstrand leaves Swedbank’s Board of Directors

Josefin Lindstrand has notified that she will leave Swedbank’s Board of Directors to accept other board positions within the industry of financial technology and products.“Josefin Lindstrand has contributed in an excellent way to Swedbank’s considerable progress in leaving the historical AML-issues behind. I wish Josefin all the best in her new positions where I am convinced that her competence will prove itself very valuable,” says Göran Persson, Chair of Swedbank’s Board of Directors. Josefin Lindstrand who has served on Swedbank’s Board of Directors since 2019 leaves her position

Lancet’s EClinicalMedicine publishes phase 2 data on C21 in COVID-19

· The trial showed that C21 reduced the need for supplemental oxygen and mechanical ventilation, indicating faster patient recovery. C21 was also found to be safe and well tolerated. · Data encouraged Vicore to move into phase 3 with readout on-track for H1 2022.Gothenburg, October 25, 2021 - Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the results of the COVID-19 phase 2 trial of its angiotensin II type 2 receptor agonist C21 have been published in EClinicalMedicine, a

Embellence Group Interim Report Q3 2021

Tentative demand during hot summer monthsThird quarter of 2021 · Net sales amounted to MSEK 135.5 (130.8), up 3.6% · Adjusted EBITA amounted to MSEK 18.3 (21.4), down 14.2% · EBITA amounted to MSEK 18.3 (21.2), down 13.4% · Net profit for the period amounted to MSEK 12.2 (12.7) and earningsper share before dilution for the period were SEK 0.57 (0.59) · Operating cash flow amounted to MSEK 16.1 (18.9) Significant events during the quarter · Robert Shams Smolander appointed Head of Group Change Management & Sustainability Significant events after the end of the

Yet another strong quarter

Financial highlights July – September 2021 · Net sales increased by 44.6 percent to EUR 34.3m (23.7). Organic growth excluding currency effects was 34.0 percent · Gross profit amounted to EUR 17.5m (12.0) with a gross margin of 50.9 percent (50.7) · Adjusted EBITDA amounted to EUR 6.6m (3.8) with an adjusted EBITDA margin of 19.4 percent (16.2). Adjusted EBITDA, excluding the FX effect from the revaluation of operating balance sheet items, amounted to EUR 5.9m (4.2) and the margin 17.2% (17.8) · Adjusted earnings per share, before and after dilution amounted to EUR 0.03 (0.

Rock Energy

After the recent name change to GET Group, an update from the group’s largest subsidiary Rock Energy is presented in a video that has now been published on our website getgroup.se today at 08:00 CET. GET Group is an investment company focused on energy and sustainability. We are creating the world’s most compelling listed ESG tech-company, by owning and financing the unique technology companies that are committed to energy production and energy saving. Link to video: Rock Energy 

GomSpace (provider of nanosatellites) announces its quarterly results for the third quarter 2021

Stockholm, October 25, 2021. GomSpace Group AB (the “Company”) announces its interim report for the third quarter of 2021. The report is available on the Company’s homepage (www.gomspace.com). The following is taken from the quarterly report: Third quarter summary 1 July – 30 September 2021 (2020) · Order intake decreased to T.SEK 43,034 (136,472) · Net revenues increased to T.SEK 49,700 (39,136) · Gross margin decreased to 20% (24%) · Operating profit (loss) were a negative T.SEK 7,240 (a negative 7,234) · Earnings per share were a negative SEK 0.14 (a negative 0.14)

Hexagon Composites ASA: Invitation to presentation of third quarter results 2021

Hexagon Composites ASA’s third quarter results 2021 will be released on 4 November 2021, 07:00 CET. Jon Erik Engeset (CEO) and David Bandele (CFO) will present the results at 08:30 CET. The presentation will be held in the Auditorium at Hexagon’s location in Oslo, Haakon VIIs gate 2, on the lower level. As Covid-19 restrictions are lifted in Norway, we welcome those that want to attend the presentation in person. The presentation will also be broadcasted live via: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20211104_16.A recording of the presentation will be made

Dennis Andersson new CEO of Swedish Stirling

Clean-tech company Swedish Stirling AB (publ) carries out a CEO succession on 15 November 2021 when Dennis Andersson will become the new CEO. Dennis takes over a company that has successfully landed the first commercial agreements concerning its PWR BLOK-technology and that is entering into a clear industrialization phase.The board of Swedish Stirling has appointed Dennis Andersson as new CEO of the company. Dennis will take up the position on 15 November 2021. He is currently deputy CEO and Chief Marketing & Sales Officer of the company. He was hired by the company in June 2020 and came

Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults

Desentum Oy, a clinical-stage biopharmaceutical company developing novel immuno­therapies for treating allergies, today announced positive First-in-Human clinical data of DM-101, its lead candidate for treatment of birch pollen allergy. DM-101 was found to be safe and well tolerated in a dose regimen of 5 ascending doses, and immunological marker results indicated a favourable immunological response.“We are very happy to have completed the clinical study despite the challenges posed by the Covid-19 pandemic. The preclinical models available for testing allergen immunotherapy products are

There are no items matching the current filter
There are no more items matching the current filter
Back to top